PASADENA, CA — A study released in The Lancet Respiratory Medicine shows that a booster dose of the Pfizer COVID-19 vaccine provides strong protection, roughly 80 percent to 90 percent, in the first few months against hospital admissions and emergency department visits caused by the Delta and Omicron variants. However, against Omicron, this protection wanes over time—even after a third dose.
“Pfizer BioNTech COVID-19 booster doses significantly improve protection against Omicron, although that protection seems to wane after three months against emergency room visits, and even for hospitalization,” said the study’s lead author, Sara Y. Tartof, PhD, an epidemiologist with the Kaiser Permanente Southern California Department of Research & Evaluation and a faculty member of the Kaiser Permanente Bernard J. Tyson School of Medicine, both in Pasadena. “Trends in waning against Delta-related outcomes were generally similar to Omicron, but with higher effectiveness at each time point than those seen for Omicron.”
For this study, the researchers analyzed 11,123 hospital admissions and emergency department visits that did not result in hospital admission for acute respiratory infection. The study focused on Kaiser Permanente patient records in Southern California from December 1, 2021, through February 6, 2022, when both the Delta and Omicron variants were circulating.
- After two doses of the Pfizer COVID-19 vaccine effectiveness against Omicron was 41 percent against hospital admission and 31 percent against emergency department visits at nine months.
- After three doses, effectiveness against Omicron-related hospitalization was 85 percent at less than three months but fell to 55 percent at three months or longer.
- Against emergency department visits that did not result in hospitalization, vaccine effectiveness of three doses against omicron was 77 percent at less than three months but fell to 53 percent at three months or longer.
“Although the Pfizer COVID-19 protection levels against omicron after 3 doses are substantially higher than those seen after 2 doses, they are less than those observed for delta or other COVID-19 strains,” Tartof said. “Additional doses of current, adapted, or novel COVID-19 vaccines may be needed to maintain high levels of protection against subsequent waves of COVID-19 caused by omicron or future variants with similar potential to escape protection.”
- This press release was provided by Kaiser Permanente